Amiodarone, a bi-iodinated benzofuran derivative, is among the most commonly used antiarrhythmic drugs due to its high level of effectiveness. Though initially categorized as a class III agent, amiodarone exhibits antiarrhythmic properties across all four classes of antiarrhythmic drugs. Amiodarone is highly effective in maintaining sinus rhythm in patients with paroxysmal atrial fibrillation while also playing a crucial role in preventing a range of ventricular arrhythmias. Amiodarone has a complex pharmacokinetic profile, characterized by a large volume of distribution and a long half-life, which can range from several weeks to months, resulting in prolonged effects even after discontinuation. Side effects may include thyroid dysfunction, pulmonary fibrosis, and hepatic injury, necessitating regular follow-ups. Additionally, amiodarone interacts with several drugs, including anticoagulants, which must be managed to prevent adverse effects. Therefore, a deep understanding of both oral and intravenous formulations, as well as proper dosage adjustments, is essential. The aim of this paper is to provide a comprehensive and updated review on amiodarone's indications, contraindications, recommended dosages, drug interactions, side effects, and monitoring protocols.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11508869 | PMC |
http://dx.doi.org/10.3390/jcm13206094 | DOI Listing |
Background: The most effective way to treat patients following a first ICD therapy is unclear. We hypothesised that following first ICD therapy, combining different treatment strategies would be associated with a reduction in the risk of subsequent therapy compared to single strategies alone.
Methods: Data was collected from consecutive patients undergoing ICD implantation at King's College Hospital between January 2009 and December 2019.
ACS Appl Mater Interfaces
January 2025
Department of Chemical Engineering and Environmental Technology, Universidad de Zaragoza, Campus Río Ebro-Edificio I+D, 50018 Zaragoza, Spain.
The emergence of green chemistry and engineering principles to enforce sustainability aspects has ensured the prevalence of green solvents and green processes. Our study addresses this quest by exploring drug delivery applications of hydrophobic deep eutectic solvents (DESs) which are alternative green solvents. Initially, this work showcases the hydrophobic drug solubilization capabilities of a natural hydrophobic DES, menthol, and decanoic acid.
View Article and Find Full Text PDFMol Cancer
January 2025
Department of Gastric Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, 510060, People's Republic of China.
The N6-methyladenosine (m6A) modification serves as an essential epigenetic regulator in eukaryotic cells, playing a significant role in tumorigenesis and cancer progression. However, the detailed biological functions and underlying mechanisms of m6A regulation in gastric cancer (GC) are poorly understood. Our research revealed that the m6A demethylase ALKBH5 was markedly downregulated in GC tissues, which was associated with poor patient prognosis.
View Article and Find Full Text PDFChem Biodivers
January 2025
Yunnan University, School of Chemical Science and Technologe, Cuihu Bei Road, Kunming, CHINA.
Kaurane-class diterpenoid alkaloids (DAs), an important group of C20-DAs, include mainly veatchine-, napelline-, anopterine- and tricalysiamide-type DAs and several types of DAs with novel skeletons discovered in recent years. To date, approximately 81 compounds belonging to this class of DAs have been isolated from plants in 5 families and 7 genera. Among them, Aconitum is the most important source of this class of DAs.
View Article and Find Full Text PDFPost-operative new-onset atrial fibrillation (POAF) is a possible complication following cardiac surgery. Digoxin is a drug with positive inotropic and negative chronotropic effects and is listed among antiarrhythmic drugs that can be prescribed in dogs with atrial fibrillation. This report aims at describing the use of digoxin in two dogs with persistent POAF after mitral valve repair.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!